TRCT
KNSA icon

Tower Research Capital (TRC)’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Tower Research Capital (TRC)’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.2K Sell
254
-125
-33% -$5.54K ﹤0.01% 3803
2025
Q4 		$15.6K Buy
379
+325
+602% +$13K ﹤0.01% 3283
2025
Q3 		$2.1K Sell
54
-25,221
-100% -$819K ﹤0.01% 4683
2025
Q2 		$699K Buy
25,275
+23,733
+1,539% +$604K 0.02% 730
2025
Q1 		$34.2K Sell
1,542
-6,941
-82% -$143K ﹤0.01% 2516
2024
Q4 		$168K Buy
8,483
+4,575
+117% +$104K ﹤0.01% 1835
2024
Q3 		$97.7K Buy
+3,908
New +$95.2K ﹤0.01% 2252
2024
Q2 		– Sell
-758
Closed -$15K – 5863
2024
Q1 		$15K Sell
758
-9,534
-93% -$186K ﹤0.01% 3273
2023
Q4 		$181K Buy
10,292
+9,008
+702% +$148K ﹤0.01% 2186
2023
Q3 		$22.3K Sell
1,284
-918
-42% -$15.5K ﹤0.01% 3276
2023
Q2 		$31K Sell
2,202
-2,713
-55% -$36.3K ﹤0.01% 2993
2023
Q1 		$53K Buy
4,915
+4,001
+438% +$52.7K ﹤0.01% 2437
2022
Q4 		$13K Sell
914
-2,163
-70% -$31.5K ﹤0.01% 3616
2022
Q3 		$39K Sell
3,077
-1,203
-28% -$13.7K ﹤0.01% 3378
2022
Q2 		$42K Buy
4,280
+1,755
+70% +$16.4K ﹤0.01% 3056
2022
Q1 		$25K Sell
2,525
-5,459
-68% -$57.8K ﹤0.01% 3325
2021
Q4 		$94K Buy
7,984
+3,510
+78% +$43.1K ﹤0.01% 2268
2021
Q3 		$50K Sell
4,474
-1,027
-19% -$13.4K ﹤0.01% 2963
2021
Q2 		$77K Buy
5,501
+4,167
+312% +$63.3K ﹤0.01% 2642
2021
Q1 		$25K Sell
1,334
-1,416
-51% -$29K ﹤0.01% 3707
2020
Q4 		$49K Sell
2,750
-16,671
-86% -$293K ﹤0.01% 3143
2020
Q3 		$298K Buy
19,421
+16,733
+623% +$314K ﹤0.01% 2196
2020
Q2 		$68K Buy
2,688
+1,254
+87% +$26.2K ﹤0.01% 2798
2020
Q1 		$22K Sell
1,434
-5,380
-79% -$84.2K ﹤0.01% 1668
2019
Q4 		$76K Buy
6,814
+6,784
+22,613% +$58.9K 0.01% 1104
2019
Q3 		$0 Buy
+30
New +$331 ﹤0.01% 4317
2019
Q2 		– Sell
-498
Closed -$9K – 3988
2019
Q1 		$9K Buy
+498
New +$9.62K ﹤0.01% 2736
2018
Q4 		– Sell
-1,199
Closed -$31K – 4105
2018
Q3 		$31K Buy
1,199
+969
+421% +$18.8K ﹤0.01% 2053
2018
Q2 		$4K Buy
+230
New +$4.16K ﹤0.01% 3139

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Tower Research Capital (TRC)'s KNSA Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Kiniksa Pharmaceuticals (KNSA) stake by 33% in Q1 2026, selling an estimated $5.54K and leaving 254 shares worth $12.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3803.

Tower Research Capital (TRC) first reported a position in KNSA in Q2 2018 and has held it in 29 quarters since. The position peaked at $699K in Q2 2025. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Tower Research Capital (TRC) held 254 shares of Kiniksa Pharmaceuticals worth $12.2K as of Q1 2026.
  • Tower Research Capital (TRC) sold 125 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $5.54K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3803 holding.
  • Tower Research Capital (TRC) first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Kiniksa Pharmaceuticals position peaked at $699K in Q2 2025.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.